fda glp-1 compounded warning september 2025 🚨 Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of medications like semaglutide and tirzepatide, signaling a major shift in how these FDA warns telehealth providers over

[63] Survodutide, Mazdutide, Pemvidutide, MariTide, Ecnoglutide, and Bimagrumab Other emerging therapies include dual GLP-1/glucagon receptor agonists such as survodutide, mazdutide, and pemvidutide, long-acting antibody-based or peptide-conjugate approaches such as maridebart cafraglutide (MariTide), biased GLP-1 receptor agonists such as ecnoglutide, and body-composition-targeted therapies such as bimagrumab, which targets activin type II receptors to reduce fat mass while preserving or increasing lean mass

Loren Pickart Pickart, Loren a world- renowned biochemist known for his significant contributions to the field of skin biology and aging, has passed away at the age of 85

Zinc: Promotes clear skin and helps with acne control

Retrieved from: Singh, S